Yeo Crystal J J, Gilman Andrew L
*School of Clinical Medicine, University of Cambridge, Cambridge, UK †Division of Blood and Marrow Transplantation, Levine Children's Hospital, Charlotte, NC.
J Pediatr Hematol Oncol. 2014 Mar;36(2):e78-80. doi: 10.1097/MPH.0b013e31828e5c56.
Biallelic BRCA2 mutations occur in 2% of patients with Fanconi anemia and are associated with a high risk of acute leukemia at an early age and a poor prognosis. For the first time, we report the use of interleukin-2 to stimulate a graft-versus-leukemia effect and induce complete remission in a patient with BRCA2 Fanconi anemia and refractory acute myelogenous leukemia, suggesting the potential of immunotherapy in this setting. Interleukin-2 was associated with significant infusion-related toxicity.
